Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma × imgatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 1 Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 5 nimotuzumab 2 X-Rays 2 Radiotherapy 2 Magnetic Resonance Spectroscopy 2 trifluridine tipiracil drug combination 1 sargramostim 1 palladium-bacteriopheophorbide 1 padeliporfin 1 imgatuzumab 1 galactomannan 1 futuximab 1 fluoromisonidazole 1 capmatinib 1 cabozantinib 1 Tomography, Optical Coherence 1 Standard of Care 1 Specimen Handling 1 Ramucirumab 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Image-Guided 1 Practice Guidelines as Topic 1 Platinum 1 Nivolumab 1 N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1 Mitomycin 1 LMB-100 1 Ipilimumab 1 Interviews as Topic 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04985825 2022-09-13

I-PACE

Centessa Pharmaceuticals plc

Phase 2 Withdrawn

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡